Krystina E. Kattermann

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

M. Mino‐Kenudson, L. Sequist, J. Engelman, 2021, Cancer cell.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Joshua M. Korn, J. Korn, P. Hammerman, 2019, Oncogene.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

M. Lawrence, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, J. Engelman, 2018, Cancer discovery.